CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic ...
47 percent of patients had complete response; median overall survival 15.5 months with decitabine-cedazuridine plus venetoclax.
Addition of TUS to standard of care VEN+AZA creates a well-tolerated and mutation agnostic frontline triple drug therapy for newly diagnosed ...
OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –– 96% CRc in newly ...
A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia (AML) overcome resistance to one of the most ...
Aptevo Therapeutics (APVO) announced 100% of patients achieved remission within 30 days, in Cohort 1 of the RAINIER frontline acute myeloid leukemia Phase 1b trial, including two patients who ...
Akeso, Inc. (9926.HK) ('Akeso' or the 'Company') today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results